Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Personalized chemotherapy guidance using patient-derived scaffolds from peritoneal colorectal metastases.

Experimental hematology & oncology·2026
Same author

Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Disabling aggressive colorectal cancer by dual targeting of cancer cells and the microenvironment.

Cancer letters·2026
Same author

Survival and morbidity in elderly patients treated with cytoreductive surgery and HIPEC for colorectal peritoneal metastases: a population-based study.

International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·2026
Same author

Early Specialized Palliative Care for Unresectable Pancreatic Cancer: A Quasi-Experimental Study.

Journal of pain and symptom management·2025
Same author

Early response prediction during radiotherapy in rectal cancer using sequential diffusion-weighted imaging at a magnetic resonance image-guided linear accelerator.

Physics and imaging in radiation oncology·2025

Related Experiment Video

Updated: Mar 6, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

974

Neoadjuvant Chemotherapy vs Upfront Surgery in Patients With Locally Advanced Colon Cancer: A Randomized Clinical

Lars Henrik Jensen1, Monica Kjaer2,3, Laura Vittrup Diness4

  • 1Danish Colorectal Cancer Center South, Oncology, University Hospital of Southern Denmark, Vejle Hospital, Vejle, Denmark.

JAMA Surgery
|March 4, 2026
PubMed
Summary

Neoadjuvant chemotherapy did not improve disease-free survival (DFS) for locally advanced colon cancer compared to upfront surgery. However, it showed feasibility, safety, and potential benefits in specific patient subgroups, warranting further research.

More Related Videos

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
12:45

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Published on: February 12, 2022

6.8K
Surgical Robot-Assisted Transanal Specimen Extraction Radical Sigmoidectomy Without an Auxiliary Abdominal Incision
07:22

Surgical Robot-Assisted Transanal Specimen Extraction Radical Sigmoidectomy Without an Auxiliary Abdominal Incision

Published on: June 13, 2025

1.1K

Related Experiment Videos

Last Updated: Mar 6, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

974
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
12:45

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Published on: February 12, 2022

6.8K
Surgical Robot-Assisted Transanal Specimen Extraction Radical Sigmoidectomy Without an Auxiliary Abdominal Incision
07:22

Surgical Robot-Assisted Transanal Specimen Extraction Radical Sigmoidectomy Without an Auxiliary Abdominal Incision

Published on: June 13, 2025

1.1K

Area of Science:

  • Oncology
  • Clinical Trials
  • Surgical Oncology

Background:

  • Locally advanced colon cancer has a high recurrence risk.
  • Neoadjuvant chemotherapy is a potential treatment to improve outcomes.
  • Evidence from phase III trials for neoadjuvant chemotherapy in colon cancer is limited.

Purpose of the Study:

  • To evaluate if neoadjuvant chemotherapy improves disease-free survival (DFS) versus upfront surgery.
  • To compare neoadjuvant chemotherapy followed by surgery against upfront surgery followed by adjuvant chemotherapy.

Main Methods:

  • A randomized, open-label, phase III clinical trial involving 250 patients.
  • Patients were assigned to either upfront surgery or neoadjuvant capecitabine and oxaliplatin followed by surgery.
  • Disease-free survival (DFS) was the primary endpoint, with follow-up up to 3 years.

Main Results:

  • At 3 years, DFS was 87% in the upfront surgery arm and 83% in the neoadjuvant arm (P=.36).
  • Neoadjuvant chemotherapy was feasible, safe, and achieved tumor downstaging.
  • Reduced need for adjuvant chemotherapy was observed in the neoadjuvant group (59% vs 73%).

Conclusions:

  • Neoadjuvant chemotherapy did not improve DFS compared to upfront surgery in locally advanced colon cancer.
  • The study suggests feasibility, safety, and downstaging benefits of neoadjuvant chemotherapy.
  • Exploratory findings on mismatch repair (MMR) status indicate potential for individualized treatment strategies.